EMA Authorised: Idelvion (albutrepenonacog alfa) — CSL Behring GmbH

View source ↗

Summary

The European Medicines Agency authorised Idelvion (albutrepenonacog alfa) by CSL Behring for Hemophilia B, marking EU marketing approval; it carries orphan medi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• IdElvion

Snippet

Status: Authorised. Therapeutic area: Hemophilia B. MAH: CSL Behring GmbH. Decision date: 17/12/2024. Orphan medicine